contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-oyj-herantis-appoints-tone-kvale-as-chief-financial-officer

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

What on earth is this again? Could you have at least put a disclaimer at the start that this is random AI-generated speculation that isn’t based on anything? I wasted three minutes of my life looking for news related to this.

Aspen Neuroscience’s cell therapy for Parkinson’s disease is also now moving into a pivotal stage. https://www.fiercebiotech.com/biotech/aspens-one-year-data-parkinsons-cell-therapy-plants-seeds-ph-3-trial Here is also a link to the company’s IR page press release: Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases  Aspen’s therapy uses the patient’s own programmed iPS cells as a source for dopaminergic cells to avoid an immune response against the graft. This is a very expensive way to manufacture the therapy, so it remains to be seen how commercially viable it will ultimately be.

CFO added a small slice.                   Inderes              Herantis Pharma Oyj: Johdon liiketoimet – Tone Kvåle - Inderes    Herantis Pharma OyjYhtiötiedote 10.3.2026 kello 13:00Herantis Pharma Oyj: Johdon liiketoimet – Tone KvåleHerantis Pharma Oyj - Johdon liiketoimet____________________________________________Ilmoitusvel...

A clear answer regarding the outlook for the formation of Herantis Pharma’s partnership agreement. https://x.com/ristopar/status/2030476177870131641/video/1

Here is a fresh company report from Antti regarding Herantis’s H2  Herantis’s main theme for 2025 was the completion of the Phase I study. All objectives of the study were achieved, providing a solid scientific basis for the future. The company’s estimate of the remaining funding requirement for the Phase II study is 20–25 MEUR, which is in line with our forecast. The next critical step is securing funding for the study, which in our assessment involves significant binary risk depending on the solution reached. We are modeling our estimate for follow-on funding and adjusting our target price to EUR 2.4 (prev. EUR 2.5) following the changes. We upgrade our recommendation to Accumulate (prev. Reduce) as the share price decline has improved the risk-reward ratio.                   Inderes              Herantis H2'25: Rahoitus kuntoon ja uuden tutkimuksen alkuun - Inderes    Herantis valmistautuu rahoitusratkaisuihin ja seuraavan tutkimuksen aloittamiseen.

Good interview of Antti by Antti. Vuolanto’s demeanor is quite confident and calm. 2025 went successfully, results were good and the feedback from Big Pharma (BP) and experts was excellent. This year has started off brilliantly regarding Phase II funding, and his answers really exude positive confidence that the funding will be secured on schedule.                   Inderes              Herantis Pharma H2'25: Vahva pohja vaiheen II tutkimuksen aloittamiselle -...    Aika: 05.03.2026 klo 12.06 Herantis Pharma eteni vuonna 2025 suunnitelmien mukaisesti ja vaiheen 1b tutkimus saavutti tavoitteet.

In my opinion, Herantis Pharma’s communications have been of very high quality in all respects. Essential matters have been reported well in advance and according to the actual situation, to the extent permitted by the Companies Act.

Herantis Pharma

Herantis Pharma Plc Company release, [26 October 2020 at 9:35 a.m.] Eastern European TimeHerantis Pharma Plc ("Herantis"), an innovative drug development company aiming to transform standard...

Herantis Pharma Plc Company release, [26 October 2020 at 9:35 a.m.] Eastern European TimeHerantis Pharma Plc ("Herantis"), an innovative drug development company aiming to transform standard therapeutic approaches with its leading biologic and gene therapy, announces the appointment of Tone Kvåle as Chief Financial Officer and member of the management team, effective immediately.Tone is a seasoned financial executive with a strong track record of more than 20 years of financial experience in the biotech and life sciences industry.  Most recently, Tone was CFO at Nordic Nanovector, a publicly listed company in Norway, for 7 years, and prior to that held CFO roles at NorDiag, Kavli Holding, Dynal Biotech, as well as senior management positions at Invitrogen/Life Technologies, in US, now part of Thermo Fisher.  In these roles she helped the companies raise over EUR 200m in financing, was involved in several trade sales, M&amp;A and licensing deals, and was responsible for financial reporting under various reporting standards including US GAAP and IFRS.  Tone has a diploma in finance and administration from UiT The Arctic University of Norway, Harstad."We are delighted to welcome Tone to Herantis' management team. She brings considerable financial acumen, public company biotech experience, and strategic skills that will be invaluable to the company.  Tone's joining comes as Herantis enters its next chapter and progresses our pipeline of groundbreaking biological and gene therapy drugs in neurodegenerative and lymphatic diseases, a pivotal stage in the company's development. We look forward to Tone being a key part of our future success," commented Craig Cook, CEO.Tone Kvåle, CFO, commented "I am excited to take on the CFO role at Herantis and very much look forward to working with the entire team, building on the company's momentum, ambition, and strong biotech fundamentals.  I was drawn to Herantis because of its science promising to bring innovations that address critical gaps in the current standard of care for patients with these diseases."For more information, please contact: Julie Silber/Gabriela Urquilla Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19 <virtloc>Email:ir@herantis.com</virtloc>Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400Company website: www.herantis.com  About Herantis Pharma Plc Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson's disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.